Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Egrifta Quality Of Life Deciding Factor In Advisory Panel's Recommendation

Executive Summary

Improving patients' quality of life seemed to be more important than an unproven cardiovascular benefit in an FDA advisory panel's unanimous vote to recommend approval of Theratechnologies' Egrifta (tesamorelin), indicated for reduction of visceral adipose tissue in HIV patients receiving antiretroviral therapy

You may also be interested in...



Egrifta Approval: FDA Balanced Modest Efficacy, Off-Label Use Potential With Unmet Medical Need

The approval of Theratechnologies’ HIV lipodystrophy treatment Egrifta (tesamorelin) shows how much FDA can be swayed by unmet need, even where the product has limited efficacy in a narrow population and substantial potential for off-label use.

Egrifta Approval: FDA Balanced Modest Efficacy, Off-Label Use Potential With Unmet Medical Need

The approval of Theratechnologies’ HIV lipodystrophy treatment Egrifta (tesamorelin) shows how much FDA can be swayed by unmet need, even where the product has limited efficacy in a narrow population and substantial potential for off-label use.

FDA Finds Creative Labeling Solution For Egrifta Patient-Reported Outcomes Data

FDA faces a challenge when it receives results from a patient-reported outcomes tool that it does not think is properly validated, but was designed in consultation with the agency.

Related Content

Topics

UsernamePublicRestriction

Register

PS052276

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel